Protalix BioTherapeutics Cash Flow Statement (2010-2025) | PLX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Operating Activities
Net Income (Quarter)	-5.86M	-11.37M	-4.29M	-6.61M	-2.29M	-5.33M	-3.57M	-3.21M	-3.13M	19.34M	-1.85M	-18.58M	-4.59M	-2.20M	3.24M	11.28M	-3.62M	0.16M	2.41M	-1.10M
Depreciation and Depletion (Quarter)	0.29M	0.29M	0.28M	0.24M	0.27M	0.27M	0.27M	0.29M	0.28M	0.29M	0.30M	0.31M	0.32M	0.32M	0.33M	0.33M	0.35M	0.36M	0.37M	0.39M
Share-based Compensation (Quarter)	0.82M	0.38M	0.07M	0.42M	0.84M	0.17M	0.04M	0.54M	0.55M	0.25M	0.20M	1.37M	0.98M	1.00M	0.62M	0.65M	0.54M	0.43M	0.60M	0.73M
Deferred Taxes (Quarter)										-3.13M	0.04M		-0.14M	-0.07M	0.44M		-0.11M	0.23M	0.06M	0.16M
Cash from Discontinued Operations (Quarter)
Gains from Sales and Divestitures (Quarter)				0.17M				0.93M				0.49M				0.99M			0.05M	0.69M
Gains from Investment Securities (Quarter)	0.12M	-0.07M	0.03M	0.23M	0.03M	0.04M	-0.53M	1.22M	0.31M	-0.27M	0.01M	1.52M	0.01M	0.01M	-0.01M	0.38M	0.03M	-0.02M	1.45M	1.16M
Non-cash Items (Quarter)				0.96M				1.20M				2.60M				1.00M				5.46M
Cash from Operations (Quarter)	-9.83M	6.52M	-1.88M	-5.09M	-5.83M	-7.36M	-9.20M	-2.61M	-3.00M	4.97M	-6.89M	3.60M	4.19M	-3.61M	4.11M	3.99M	-5.06M	-5.23M	-3.73M	2.03M
Depreciation, Depletion & Amortization
Amortization of Deferred Charges (Quarter)	0.94M	0.98M	0.64M	0.10M	0.07M	0.07M	0.08M	0.08M	0.08M	0.07M	0.06M	0.06M
Depreciation & Amortization (CF) (Quarter)	0.29M	0.29M	0.28M	0.24M	0.27M	0.27M	0.27M	0.29M	0.28M	0.29M	0.30M	0.31M	0.32M	0.32M	0.33M	0.33M	0.35M	0.36M	0.37M	0.39M
Change in Working Capital
Change in Receivables (Quarter)	2.28M	-0.69M	2.49M	-3.04M	2.31M	-2.39M	5.77M	-4.50M	-3.82M	3.70M	4.31M	-3.76M	-1.75M	7.05M	-8.38M	0.75M	2.27M	4.64M	4.85M	-5.88M
Change in Inventory (Quarter)	0.83M	-0.28M	1.09M	3.22M	-1.36M	-0.09M	-1.95M	2.24M	3.50M	-0.67M	1.95M	-2.54M	3.30M	-1.63M	-3.52M	4.04M	-1.74M	1.62M	0.12M	4.47M
Change in Accured Expenses (Quarter)	0.57M	-1.12M	1.61M	1.31M	-1.01M	-3.85M	0.43M	-0.37M	0.35M	3.29M	0.18M	1.48M	-1.41M	1.61M	-0.87M	1.37M	-1.28M	-0.61M	-2.14M	4.33M
Other Working Capital Changes (Quarter)	-0.03M	12.29M	1.68M	-0.71M	-2.64M		-2.90M	-1.61M	-1.39M	-11.79M			11.04M	1.66M		0.25M
Investing Activities
Capital Expenditures (Quarter)	0.39M	0.28M	0.34M	-0.92M	0.23M	-0.15M	0.33M	0.21M	0.33M	0.13M	0.45M	0.25M	0.15M	0.62M	0.09M	-0.60M	0.31M	0.43M	0.50M	-0.87M
Sales of Property, Plant and Equipment (Quarter)	0.05M
Cash from Investing Activities (Quarter)	-30.68M	7.54M	4.63M	37.44M	-16.26M	0.36M	5.91M	4.95M	4.73M	-0.22M	-20.88M	-0.34M	-0.61M	-0.18M	20.33M	-15.32M	-0.31M	-0.44M	-0.50M	-1.11M
Financing Activities
Cash from Financing Activities (Quarter)	42.11M		-25.99M	-4.05M			1.52M	4.08M	14.23M	10.43M						3.63M	5.08M	4.10M		0.15M
Additional items
Exchange Rate Effect (Quarter)	-0.03M	-0.00M	0.00M	0.04M	-0.01M	-0.04M		-0.03M	-0.04M	-0.04M	-0.01M	-0.03M	-0.01M	-0.02M	-0.00M	0.05M	-0.01M	0.00M	-0.01M	-0.03M
Change in Cash (Quarter)	1.56M	14.05M	-23.24M	28.34M	-22.10M	-4.40M	-1.77M	6.39M	15.93M	15.15M	-27.78M	3.23M	3.58M	-3.81M	4.01M	-7.65M	-0.30M	-1.56M	-4.25M	1.03M
Free Cash Flow (Quarter)	-10.22M	6.24M	-2.22M	-4.17M	-6.06M	-7.21M	-9.54M	-2.82M	-3.32M	4.85M	-7.33M	3.35M	4.04M	-4.23M	4.02M	4.59M	-5.36M	-5.66M	-4.23M	2.90M
Net Cash Flow (Quarter)	1.60M	14.06M	-23.24M	28.30M	-22.09M	-7.00M	-1.77M	6.42M	15.97M	15.18M	-27.77M	3.25M	3.58M	-3.79M	24.43M	-7.70M	-0.29M	-1.57M	-4.24M	1.06M

Research Tools

Protalix BioTherapeutics Cash Flow Statement (2010-2025) | PLX

Create an account

Sign In

Reset Password